Cargando…

The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study

The study aims to investigate the effect of repeated infusions of recombinant erythropoietin (EPO) on plasma brain derived neurotrophic factor (BDNF) levels in patients with affective disorders. In total, 83 patients were recruited: 40 currently depressed patients with treatment-resistant depression...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinberg, Maj, Miskowiak, Kamilla, Hoejman, Pernille, Pedersen, Maria, Kessing, Lars Vedel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444304/
https://www.ncbi.nlm.nih.gov/pubmed/26011424
http://dx.doi.org/10.1371/journal.pone.0127629
_version_ 1782373127546732544
author Vinberg, Maj
Miskowiak, Kamilla
Hoejman, Pernille
Pedersen, Maria
Kessing, Lars Vedel
author_facet Vinberg, Maj
Miskowiak, Kamilla
Hoejman, Pernille
Pedersen, Maria
Kessing, Lars Vedel
author_sort Vinberg, Maj
collection PubMed
description The study aims to investigate the effect of repeated infusions of recombinant erythropoietin (EPO) on plasma brain derived neurotrophic factor (BDNF) levels in patients with affective disorders. In total, 83 patients were recruited: 40 currently depressed patients with treatment-resistant depression (TRD) (Hamilton Depression Rating Scale-17 items (HDRS-17) score >17) (study 1) and 43 patients with bipolar disorder (BD) in partial remission (HDRS-17 and Young Mania Rating Scale (YMRS) ≤ 14) (study 2). In both studies, patients were randomised to receive eight weekly EPO (Eprex; 40,000 IU) or saline (0.9% NaCl) infusions in a double-blind, placebo-controlled, parallel—group design. Plasma BDNF levels were measured at baseline and at weeks 5, 9 and at follow up, week 14. In contrast with our hypothesis, EPO down regulated plasma BDNF levels in patients with TRD (mean reduction at week 9 (95% CI): EPO 10.94 ng/l (4.51-21.41 ng/l); mean increase at week 9: Saline 0.52 ng/l, p=0.04 (-5.88-4.48 ng/l) p=0.04, partial ŋ(2)=0.12). No significant effects were found on BDNF levels in partially remitted patients with BD (p=0.35). The present effects of EPO on BDNF levels in patients with TRD point to a role of neurotrophic factors in the potential effects of EPO seen in TRD and BD. The neurobiological mechanisms underlying these effects and the interaction between EPO and peripheral levels on BDNF need to be further elucidated in human studies including a broad range of biomarkers. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00916552.
format Online
Article
Text
id pubmed-4444304
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44443042015-06-16 The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study Vinberg, Maj Miskowiak, Kamilla Hoejman, Pernille Pedersen, Maria Kessing, Lars Vedel PLoS One Research Article The study aims to investigate the effect of repeated infusions of recombinant erythropoietin (EPO) on plasma brain derived neurotrophic factor (BDNF) levels in patients with affective disorders. In total, 83 patients were recruited: 40 currently depressed patients with treatment-resistant depression (TRD) (Hamilton Depression Rating Scale-17 items (HDRS-17) score >17) (study 1) and 43 patients with bipolar disorder (BD) in partial remission (HDRS-17 and Young Mania Rating Scale (YMRS) ≤ 14) (study 2). In both studies, patients were randomised to receive eight weekly EPO (Eprex; 40,000 IU) or saline (0.9% NaCl) infusions in a double-blind, placebo-controlled, parallel—group design. Plasma BDNF levels were measured at baseline and at weeks 5, 9 and at follow up, week 14. In contrast with our hypothesis, EPO down regulated plasma BDNF levels in patients with TRD (mean reduction at week 9 (95% CI): EPO 10.94 ng/l (4.51-21.41 ng/l); mean increase at week 9: Saline 0.52 ng/l, p=0.04 (-5.88-4.48 ng/l) p=0.04, partial ŋ(2)=0.12). No significant effects were found on BDNF levels in partially remitted patients with BD (p=0.35). The present effects of EPO on BDNF levels in patients with TRD point to a role of neurotrophic factors in the potential effects of EPO seen in TRD and BD. The neurobiological mechanisms underlying these effects and the interaction between EPO and peripheral levels on BDNF need to be further elucidated in human studies including a broad range of biomarkers. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00916552. Public Library of Science 2015-05-26 /pmc/articles/PMC4444304/ /pubmed/26011424 http://dx.doi.org/10.1371/journal.pone.0127629 Text en © 2015 Vinberg et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Vinberg, Maj
Miskowiak, Kamilla
Hoejman, Pernille
Pedersen, Maria
Kessing, Lars Vedel
The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study
title The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study
title_full The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study
title_fullStr The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study
title_full_unstemmed The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study
title_short The Effect of Recombinant Erythropoietin on Plasma Brain Derived Neurotrophic Factor Levels in Patients with Affective Disorders: A Randomised Controlled Study
title_sort effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444304/
https://www.ncbi.nlm.nih.gov/pubmed/26011424
http://dx.doi.org/10.1371/journal.pone.0127629
work_keys_str_mv AT vinbergmaj theeffectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy
AT miskowiakkamilla theeffectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy
AT hoejmanpernille theeffectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy
AT pedersenmaria theeffectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy
AT kessinglarsvedel theeffectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy
AT vinbergmaj effectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy
AT miskowiakkamilla effectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy
AT hoejmanpernille effectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy
AT pedersenmaria effectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy
AT kessinglarsvedel effectofrecombinanterythropoietinonplasmabrainderivedneurotrophicfactorlevelsinpatientswithaffectivedisordersarandomisedcontrolledstudy